| Ytd | 4.95% | |
| 1y | 29.58% |
| Open | 5.17 | Prev Close | 5.21 | Low | 5.12 | High | 5.32 | Mkt Cap | 688.91M |
| Vol | 2.09M | Avg Vol | 974.95K | EPS | -0.63 | P/E | N/A | Forward P/E | 107.67 |
| Beta | 1.32 | Short Ratio | 4.50 | Inst. Own | 59.02% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-04 | 50-d Avg | 4.60 | 200-d Avg | 4.58 | 1yr Est | 8.40 |
Revvity (NYSE: RVTY - Get Free Report) and Cytek Biosciences (NASDAQ: CTKB - Get Free Report) are bo
Investors need to pay close attention to CTKB stock based on the movements in the options market lat
Cytek Biosciences, Inc. (CTKB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference T
FREMONT, Calif., and HAMBURG, Germany, Sept.
FREMONT, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- As clinical laboratories seek deeper cellular in
Deutsche Bank AG bought a new position in Cytek Biosciences, Inc. (NASDAQ: CTKB) in the undefined qu
FREMONT, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leadin
Cytek Biosciences, Inc. ("Cytek Biosciences," "Cytek," or the "Company") (NA
FREMONT, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences,” “Cy
Cytek Biosciences, Inc. (CTKB) Q2 2026 Earnings Call Transcript
Cytek Biosciences NASDAQ: CTKB reported second-quarter 2026 revenue growth of 6% year over year, sup
Cytek Biosciences, Inc. (CTKB) came out with a quarterly loss of $0.05 per share versus the Zacks Co
Cytek Biosciences (NASDAQ:CTKB) reported quarterly losses of $(0.09) per share which met the analyst
Cytek Biosciences (NASDAQ:CTKB) raises FY2026 sales outlook from $205.000 million-$212.000 million t
FREMONT, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “
Cytek Biosciences (CTKB) doesn't possess the right combination of the two key ingredients for a like
Champions Oncology and Cytek Biosciences have different growth drivers and valuations, but which lif
FREMONT, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “
US stock futures higher with Nasdaq 100 up 150 points. Ryanair (RYAAY) shares fall after weak Q1 res
FREMONT, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Spectral flow cytometry leader Cytek Biosciences,
FREMONT, Calif., June 10, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading
US stock futures higher, Nasdaq futures down. Concrete Pumping Holdings shares up 28.94% pre-market.
At CYTO 2026, Cytek will showcase its cell analysis solutions, including the public debut of a new 7
US stock futures lower, Braze Inc (BRZE) shares drop 8.4% in pre-market trading after reporting mixe
Phreesia (NYSE: PHR) shares rose in pre-market trading after better-than-expected sales results. Oth
Stephens & Co. analyst Mason Carrico maintains Cytek Biosciences (NASDAQ:CTKB) with a Overwei
Morgan Stanley analyst Tejas Savant maintains Cytek Biosciences (NASDAQ:CTKB) with a Equal-Weight
Cytek Biosciences, Inc. (CTKB) Q1 2026 Earnings Call Transcript
Cytek Biosciences, Inc. (CTKB) came out with a quarterly loss of $0.12 per share versus the Zacks Co
Cytek Biosciences (NASDAQ:CTKB) affirms FY2026 sales outlook from $205.000 million-$212.000 million
Cytek Biosciences (NASDAQ:CTKB) reported quarterly losses of $(0.15) per share which missed the anal
Cytek Biosciences (NASDAQ:CTKB) sees FY2026 sales of $205.000 million-$212.000 million vs $207.058 m
Cytek Biosciences (NASDAQ:CTKB) reported quarterly losses of $(0.34) per share which missed the anal
Cytek Biosciences, Inc. (NASDAQ: CTKB), a leading cell analysis solutions company, today announced p
TD Cowen analyst Brendan Smith maintains Cytek Biosciences (NASDAQ:CTKB) with a Buy and raises th
Piper Sandler analyst David Westenberg maintains Cytek Biosciences (NASDAQ:CTKB) with a Overweigh
Cytek Biosciences (NASDAQ:CTKB) affirms FY2025 sales outlook from $196.000 million-$205.000 million
Cytek Biosciences (NASDAQ:CTKB) reported quarterly losses of $(0.04) per share which beat the analys
FREMONT, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- In a move that strengthens its European operation
Cytek Biosciences (NASDAQ:CTKB) narrows FY2025 sales outlook from $196.000 million-$210.000 million
Cytek Biosciences (NASDAQ:CTKB) reported quarterly losses of $(0.04) per share which met the analyst
Morgan Stanley analyst Tejas Savant maintains Cytek Biosciences (NASDAQ:CTKB) with a Equal-Weight